|
Sign In to gain access to subscriptions and/or personal tools.
|
First published on February 4, 2008
Clinical and Applied Thrombosis/Hemostasis 2008, doi:10.1177/1076029607313623
© 2008 SAGE Publications
Long-Term Administration of a Low-Molecular-Weight Heparin Contributed to Successful Treatment in a Patient With Primary Mediastinal Large B-Cell Lymphoma and Venous Thromboembolism
Akio Mori, MD, PhD*,
Makoto Ibata, MD,
Shinobu Mashiko, MD,
Yutaka Tsutsumi, MD, PhD,
Nobuo Masauzi, MD, PhD,
Satoshi Hashino, MD, PhD,
Masanobu Morioka, MD, PhD,
Masahiro Asaka, MD, PhD,
and
Masahiro Imamura, MD, PhD
Hakodage Municipal Hospital
* To whom correspondence should be addressed. E-mail: Morimdphd{at}aol.com.
 |
Abstract |
|---|
The case of a 16-year-old girl with primary mediastinal large B-cell lymphoma who had thrombosis in the brachiocephalic, subclavian, and internal jugular veins at presentation is reported. MACOP-B chemotherapy plus radiation therapy could be the first-line strategy, but MACOP-B increases the risk of thrombosis. Although an effective method for initial treatment of venous thromboembolism (VTE) in cancer patients has not been established, recent studies revealed that the administration of a low-molecular-weight heparin (LMWH) was effective for secondary prevention of VTE. Therefore, the patient in this case was treated with MACOP-B plus rituximab followed by radiation therapy, and an LMWH was administered through the course of treatment. She achieved complete remission and never suffered from VTE. This case suggests that long-term administration of an LMWH contributes to the primary improvement and secondary prevention of VTE even in patients who are at high risk for thrombosis.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
|
